Bioregenx (BRGX) Capital Expenditures (2024 - 2025)

Bioregenx's (BRGX) quarterly Capital Expenditures came in at $3057.0 in Q4 2025, down 49.05% quarter-over-quarter from $6000.0 in Q3 2025.

Bioregenx (BRGX) Capital Expenditures (2024 - 2025) Analysis & Trends

Bioregenx's Capital Expenditures history runs 2 years deep, the most recent figure standing at $3057.0 for Q4 2025.

On a quarterly basis, Capital Expenditures changed N/A year-over-year to $3057.0 in Q4 2025; TTM through Dec 2025 was $9057.0, a 95.22% decrease from a year earlier, with the FY2025 full-year figure at $9057.0, down 95.22% from the prior year.
Capital Expenditures eased to $3057.0 in Q4 2025 per BRGX's latest filing, from $6000.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $189390.0 in Q1 2024 and bottomed at $3057.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Veeva Systems	29.34 Bn	22.03 Bn	662.02 Mn	1.75 Mn
2	BrightSpring Health Services	13.49 Bn	12.59 Bn	482.22 Mn	21.54 Mn
3	Healthequity	7.96 Bn	7.70 Bn	256.31 Mn	15.93 Mn
4	10x Genomics	6.17 Bn	5.63 Bn	106.18 Mn	118,000.00
5	Hinge Health	6.02 Bn	5.70 Bn	154.23 Mn	83,000.00
6	MiniMed	4.19 Bn	3.89 Bn	480.00 Mn	56.00 Mn
7	Waystar Holding	4.14 Bn	4.07 Bn	216.84 Mn	15.33 Mn
8	Doximity	3.82 Bn	3.08 Bn	125.97 Mn	-6.65 Mn
9	Privia Health	3.10 Bn	2.73 Bn	-	-978,000.00
10	Bioregenx	9.69 Mn	9.65 Mn	348,288.00	-

Download Data